Fate Therapeutics Stock Forecast, Price & News

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics or view top-rated stocks.

How has Fate Therapeutics' stock price been impacted by Coronavirus?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 61.0% and is now trading at $38.30.
View which stocks have been most impacted by COVID-19.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Fate Therapeutics.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.13. The biopharmaceutical company earned $14.23 million during the quarter, compared to analyst estimates of $8.67 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 28.25% and a negative net margin of 359.66%. The company's revenue for the quarter was up 88.3% compared to the same quarter last year. During the same period last year, the business posted ($0.36) EPS.
View Fate Therapeutics' earnings history.

What price target have analysts set for FATE?

15 brokerages have issued 12-month price objectives for Fate Therapeutics' shares. Their forecasts range from $60.00 to $145.00. On average, they expect Fate Therapeutics' share price to reach $103.13 in the next twelve months. This suggests a possible upside of 169.3% from the stock's current price.
View analysts' price targets for Fate Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:

• J. Scott Wolchko, President, Chief Executive Officer & Director (LinkedIn Profile)
• Edward J. Dulac, Chief Financial Officer & Accounting Officer (LinkedIn Profile)
• Bahram Valamehr, Chief Research & Development Officer (LinkedIn Profile)
• Wen Bo Wang, Senior Vice President-Technical Operations
• Yu Waye Chu, Senior Vice President-Clinical Development (LinkedIn Profile)

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Fate Therapeutics' key competitors?

Some companies that are related to Fate Therapeutics include argenx (ARGX), QIAGEN (QGEN), Repligen (RGEN), Ginkgo Bioworks (DNA), Neurocrine Biosciences (NBIX), Novavax (NVAX), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Abcam (ABCM), Denali Therapeutics (DNLI), Ablynx (ABLYF) and Kodiak Sciences (KOD).
View all of FATE's competitors.

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Exchange Traded Concepts LLC (0.03%), Diversified Trust Co (0.01%) and Lindbrook Capital LLC (0.00%). Company insiders that own Fate Therapeutics stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, Louis T Petrillo, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics.

Which major investors are buying Fate Therapeutics stock?

FATE stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Diversified Trust Co, and Lindbrook Capital LLC.
View insider buying and selling activity for Fate Therapeutics or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $38.30.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $3.66 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-173.39 million in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 279 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Where are Fate Therapeutics' headquarters?

Fate Therapeutics is headquartered at 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at [email protected].